Covered recipient · General Payments record
MEGAN P COUVILLION
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$5,564.92
59 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,850.00 | 2 |
| Food and Beverage | $1,635.92 | 56 |
| Education | $79.00 | 1 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $3,868.06 | 4 |
| AbbVie Inc. | $767.19 | 23 |
| Novartis Pharmaceuticals Corporation | $344.85 | 9 |
| Janssen Biotech, Inc. | $194.44 | 6 |
| Lilly USA, LLC | $80.33 | 3 |
| Amgen Inc. | $50.70 | 2 |
| E.R. Squibb & Sons, L.L.C. | $45.85 | 2 |
| Galderma Laboratories, L.P. | $41.12 | 2 |
| Journey Medical Corporation | $31.59 | 2 |
| Merz North America, Inc. | $30.58 | 1 |
| Incyte Corporation | $24.83 | 1 |
| Verrica Pharmaceuticals Inc. | $23.63 | 1 |
| UCB, Inc. | $22.72 | 1 |
| Arcutis Biotherapeutics, Inc. | $21.87 | 1 |
| GENZYME CORPORATION | $17.16 | 1 |
Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MEGAN P COUVILLION
NPI 1760724157 · CMS profile ID 2299247
Allopathic & Osteopathic Physicians / Dermatology
HOUSTON, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1760724157?year=2023&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MEGAN P COUVILLION, NPI 1760724157, CMS profile ID 2299247. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1760724157?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). MEGAN P COUVILLION, NPI 1760724157, CMS profile ID 2299247. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1760724157?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- MEGAN P COUVILLION, NPI 1760724157, CMS profile ID 2299247, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1760724157?year=2023&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
59 matching records · $5,564.92 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–59 of 59.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Lilly USA, LLC | $24.85 | 03/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031841757 | CMS |
| AbbVie Inc. | $131.03 | 03/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996530793 | CMS |
| AbbVie Inc. | $138.25 | 02/08/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996530789 | CMS |
| Lilly USA, LLC | $28.95 | 02/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031827241 | CMS |
| AbbVie Inc. | $17.36 | 02/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996530785 | CMS |
| AbbVie Inc. | $12.42 | 02/01/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996530781 | CMS |
| AbbVie Inc. | $26.08 | 01/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996530777 | CMS |
| Galderma Laboratories, L.P. | $21.23 | 01/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1059689157 | CMS |
| Journey Medical Corporation | $14.41 | 01/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1054355559 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $11,463.80 | 1 |
| PY2025 | Principal investigator | $332,965.13 | 70 |
| PY2024 | Recipient | $22,557.15 | 2 |
| PY2024 | Principal investigator | $710,780.23 | 168 |
| PY2023 | Recipient | $3,530.27 | 9 |
| PY2023 | Principal investigator | $693,857.03 | 75 |
| PY2022 | Recipient | $61.00 | 1 |
| PY2022 | Principal investigator | $798,889.10 | 43 |
| PY2021 | Principal investigator | $191,731.42 | 15 |
| PY2020 | Recipient | $8,306.70 | 2 |
| PY2020 | Principal investigator | $141,815.43 | 10 |
| PY2019 | Recipient | $45,047.50 | 2 |
| PY2019 | Principal investigator | $15,619.13 | 6 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
71 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $7,562.52 | 12/31/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202534933 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $405.00 | 12/24/2025 | Non-covered Recipient Entity Austin Institute for Clinical Research, Inc | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246430896 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $8,000.00 | 12/11/2025 | Non-covered Recipient Entity Pflugerville Derm Clinical Research | Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1252797068 |
| Principal investigator 1 | ABBVIE INC. | $8,178.05 | 12/04/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202528540 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,400.00 | 12/04/2025 | Non-covered Recipient Entity Austin Institute for Clinical Research, Inc | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246430894 |
| Principal investigator 1 | PFIZER INC. | $305.76 | 11/04/2025 | Non-covered Recipient Entity Pflugerville Dermatology Clinical Research Center Inc | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228818804 |
| Principal investigator 1 | PFIZER INC. | $2,015.50 | 10/31/2025 | Non-covered Recipient Entity Pflugerville Dermatology Clinical Research Center Inc | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228825693 |
| Principal investigator 1 | PFIZER INC. | $1,845.40 | 10/21/2025 | Non-covered Recipient Entity Pflugerville Dermatology Clinical Research Center Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228825918 |
| Principal investigator 1 | PFIZER INC. | $5,278.36 | 10/21/2025 | Non-covered Recipient Entity Pflugerville Dermatology Clinical Research Center Inc | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228826022 |
| Principal investigator 1 | ABBVIE INC. | $7,900.80 | 10/15/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202517009 |
| Principal investigator 1 | ABBVIE INC. | $7,043.32 | 10/09/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202515963 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,674.00 | 10/08/2025 | Non-covered Recipient Entity Austin Institute for Clinical Research, Inc | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246430888 |
| Principal investigator 1 | ABBVIE INC. | $210.00 | 10/02/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202513117 |
| Principal investigator 1 | ABBVIE INC. | $210.00 | 10/02/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202513119 |
| Principal investigator 1 | ABBVIE INC. | $6,390.75 | 09/18/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202511328 |
| Principal investigator 1 | ABBVIE INC. | $4,304.88 | 09/03/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202507215 |
| Principal investigator 1 | PFIZER INC. | $1,821.08 | 08/30/2025 | Non-covered Recipient Entity Pflugerville Dermatology Clinical Research Center Inc | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228841400 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,066.50 | 08/20/2025 | Non-covered Recipient Entity Austin Institute for Clinical Research, Inc | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246430886 |
| Principal investigator 1 | ABBVIE INC. | $16,453.00 | 08/14/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202504921 |
| Principal investigator 1 | ABBVIE INC. | $126.00 | 08/11/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202504195 |
| Principal investigator 1 | ABBVIE INC. | $368.80 | 08/11/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202504197 |
| Principal investigator 1 | Eli Lilly and Company | $8,300.00 | 08/11/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1187880873 |
| Principal investigator 1 | ABBVIE INC. | $4,651.09 | 08/05/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202502148 |
| Principal investigator 1 | ABBVIE INC. | $600.80 | 08/04/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202501026 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 08/04/2025 | Non-covered Recipient Entity Austin Inst For Clinic Rsrch | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175283773 |
| Principal investigator 1 | PFIZER INC. | $2,639.18 | 07/29/2025 | Non-covered Recipient Entity Pflugerville Dermatology Clinical Research Center Inc | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228849345 |
| Principal investigator 1 | ABBVIE INC. | $12,588.50 | 07/16/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202498388 |
| Principal investigator 1 | ABBVIE INC. | $9,765.22 | 07/02/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202495279 |
| Principal investigator 1 | Janssen Research & Development, LLC | $272.00 | 06/30/2025 | Non-covered Recipient Entity Austin Inst For Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175283676 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,104.00 | 06/30/2025 | Non-covered Recipient Entity Austin Inst For Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175283716 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,516.00 | 06/30/2025 | Non-covered Recipient Entity Austin Inst For Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175283744 |
| Principal investigator 1 | PFIZER INC. | $248.40 | 06/26/2025 | Non-covered Recipient Entity Pflugerville Dermatology Clinical Research Center Inc | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228851054 |
| Principal investigator 1 | Biofrontera Inc. | $6.94 | 06/25/2025 | Non-covered Recipient Entity COSMETIC LASER AND DERMATOLOGY | STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF SUPERFICIALBASAL CELL CARCINOMA(SBCC) WITH PHOTODYNAMIC THERAPY (PDT). | No dispute reported | 06/30/2026 | 1208907484 |
| Principal investigator 1 | ABBVIE INC. | $317.00 | 06/19/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202492421 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,066.50 | 06/16/2025 | Non-covered Recipient Entity Austin Institute for Clinical Research, Inc | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246430882 |
| Principal investigator 1 | ABBVIE INC. | $21,374.40 | 06/12/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202491285 |
| Principal investigator 1 | Janssen Research & Development, LLC | $574.00 | 06/05/2025 | Non-covered Recipient Entity Austin Inst For Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175283699 |
| Principal investigator 1 | ABBVIE INC. | $3,111.95 | 06/03/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202489111 |
| Recipient | Nielsen BioSciences, Inc. | $11,463.80 | 05/21/2025 | Covered Recipient Physician | CFW-3A | No dispute reported | 06/30/2026 | 1215093524 |
| Principal investigator 1 | ABBVIE INC. | $15,192.30 | 05/16/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202485297 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $533.25 | 05/15/2025 | Non-covered Recipient Entity Austin Institute for Clinical Research, Inc | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246430880 |
| Principal investigator 1 | PFIZER INC. | $1,470.08 | 05/14/2025 | Non-covered Recipient Entity Pflugerville Dermatology Clinical Research Center Inc | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228858001 |
| Principal investigator 1 | ABBVIE INC. | $3,939.60 | 05/06/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202481369 |
| Principal investigator 1 | PFIZER INC. | $1,084.85 | 05/06/2025 | Non-covered Recipient Entity Pflugerville Dermatology Clinical Research Center Inc | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228857059 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,381.00 | 04/28/2025 | Non-covered Recipient Entity Austin Inst For Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175283736 |
| Principal investigator 1 | ABBVIE INC. | $18,304.20 | 04/16/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202476990 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $533.25 | 04/11/2025 | Non-covered Recipient Entity Austin Institute for Clinical Research, Inc | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246430878 |
| Principal investigator 1 | ABBVIE INC. | $2,238.00 | 04/10/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202475815 |
| Principal investigator 1 | PFIZER INC. | $826.61 | 04/08/2025 | Non-covered Recipient Entity Pflugerville Dermatology Clinical Research Center Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228859694 |
| Principal investigator 1 | ABBVIE INC. | $6,495.56 | 04/03/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202471894 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $533.25 | 03/19/2025 | Non-covered Recipient Entity Austin Institute for Clinical Research, Inc | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246430872 |
| Principal investigator 1 | PFIZER INC. | $1,394.48 | 03/14/2025 | Non-covered Recipient Entity Pflugerville Dermatology Clinical Research Center Inc | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228862917 |
| Principal investigator 1 | ABBVIE INC. | $23,085.70 | 03/13/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | M21-417 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202463588 |
| Principal investigator 1 | Janssen Research & Development, LLC | $404.00 | 03/10/2025 | Non-covered Recipient Entity Austin Inst For Clinic Rsrch | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175283730 |
| Principal investigator 1 | Janssen Research & Development, LLC | $400.00 | 03/10/2025 | Non-covered Recipient Entity Austin Inst For Clinic Rsrch | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175283764 |
| Principal investigator 1 | ABBVIE INC. | $7,479.88 | 03/06/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202458393 |
| Principal investigator 1 | PFIZER INC. | $2,668.81 | 03/04/2025 | Non-covered Recipient Entity Pflugerville Dermatology Clinical Research Center Inc | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228862927 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,537.00 | 02/27/2025 | Non-covered Recipient Entity Austin Inst For Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175283685 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $533.25 | 02/26/2025 | Non-covered Recipient Entity Austin Institute for Clinical Research, Inc | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246430870 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $870.75 | 02/19/2025 | Non-covered Recipient Entity Austin Institute for Clinical Research, Inc | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246430868 |
| Principal investigator 1 | ABBVIE INC. | $18,988.65 | 02/13/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | M21-417 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202451501 |
| Principal investigator 1 | PFIZER INC. | $1,821.08 | 02/06/2025 | Non-covered Recipient Entity Pflugerville Dermatology Clinical Research Center Inc | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228837679 |
| Principal investigator 1 | ABBVIE INC. | $2,140.39 | 02/05/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202445645 |
| Principal investigator 1 | PFIZER INC. | $920.00 | 02/03/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE CLINICAL RESEARCH | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228853733 |
| Principal investigator 1 | Eli Lilly and Company | $360.00 | 01/31/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC | A STUDY OF LY3972406 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 1187875995 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,299.00 | 01/27/2025 | Non-covered Recipient Entity Austin Inst For Clinic Rsrch | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175283723 |
| Principal investigator 1 | PFIZER INC. | $4,209.29 | 01/24/2025 | Non-covered Recipient Entity Pflugerville Dermatology Clinical Research Center Inc | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228863773 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,066.50 | 01/22/2025 | Non-covered Recipient Entity Austin Institute for Clinical Research, Inc | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246430864 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,186.00 | 01/20/2025 | Non-covered Recipient Entity Austin Inst For Clinic Rsrch | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175283754 |
| Principal investigator 1 | ABBVIE INC. | $25,529.70 | 01/16/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | M21-417 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202439499 |
| Principal investigator 1 | Eli Lilly and Company | $23,343.00 | 01/07/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC | A STUDY OF LY3972406 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 1187875019 |